Focused On-demand Library for F-box/LRR-repeat protein 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9UKA1

UPID:

FBXL5_HUMAN

Alternative names:

F-box and leucine-rich repeat protein 5; F-box protein FBL4/FBL5; p45SKP2-like protein

Alternative UPACC:

Q9UKA1; A8MSK4; B4DIB5; Q4W5A8; Q8NHP3; Q9NXN2; Q9P0I0; Q9P0X5; Q9UJT7; Q9UKC8

Background:

F-box/LRR-repeat protein 5, also known as F-box and leucine-rich repeat protein 5 or FBL5, plays a pivotal role in iron homeostasis, DNA damage response, and protein degradation pathways. It is a component of the SCF (SKP1-cullin-F-box) protein ligase complex, targeting proteins such as IREB2/IRP2, DCTN1, and SNAI1 for ubiquitination and proteasomal degradation. This protein's activity is crucial in maintaining cellular iron levels and responding to DNA damage.

Therapeutic significance:

Understanding the role of F-box/LRR-repeat protein 5 could open doors to potential therapeutic strategies. Its involvement in iron homeostasis and DNA repair pathways presents a unique opportunity for targeting diseases where these processes are dysregulated.